Trial Profile
A single centre, open label, phase I, single ascending dose (SAD) study to investigate the safety, tolerability and pharmacokinetics of oral Capromorelin in spinal cord injury (SCI) and able-bodied volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Jun 2016
Price :
$35
*
At a glance
- Drugs Capromorelin (Primary)
- Indications Autonomic-nervous-system-disorders
- Focus Adverse reactions
- 27 Nov 2014 New trial record